PharmaShots | Incisive News in 3 Shots

Subscribe Now

PRIME Designation

$Tessa's CD30 CAR-T Therapy Receives EMA's PRIME Designation for Relapsed or Refractory Classical Hodgkin Lymphoma$

Tessa's CD30 CAR-T Therapy Receives EMA's PRIME Designation for Relapsed or Refractory Classical Hodgkin Lymphoma

January 19, 2021

AstraZeneca's MEDI8897 Receives FDA's Breakthrough Therapy Designation (BTD) & EMA's PRIME Designation for Lower Respiratory Tract Infection (LRTI) in Infants

AstraZeneca's MEDI8897 Receives FDA's Breakthrough Therapy Designation (BTD) & EMA's PRIME Designation for Lower Respiratory T...

February 5, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us